care products Stockholm, November 2019 Disclaimer Impo Important - PowerPoint PPT Presentation

Late stage development of two first-in-category wound care products Stockholm, November 2019

Disclaimer Impo Important ant infor informat mation ion You must read the following before continuing. The following applies to this document and the information provided in this prese ntation by Promore Pharma AB (publ) (the “ Company ”) or any person on behalf of the Company and any other material distributed or statements made in connection with such presentation (the “ Information ”), and you are therefore advised to carefully read the statements below before reading, accessing or making any other use of the Information. In accessing the Information, you agree to be bound by the following terms and conditions. The Information does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for, underwrite or otherwise acquire, any securities of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of the Company nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. The Information may not be reproduced, redistributed, published or passed on to any other person, directly or indirectly, in whole or in part, for any purpose. The Information is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of, or located in, any locality, state, country or other jurisdiction where such distribution or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. The Information is not for publication, release or distribution in the United States, Australia, Canada or Japan, or any other jurisdiction in which the distribution or release would be unlawful. Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (th e “ Securities Ac t”), or under the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold within the United States absent registration under the Securities Act or exemption from the registration requirement thereof. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. Any securities referred to herein cannot be offered, sold, pledged or otherwise transferred, directly or indirectly, within or into the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. This presentation does not constitute a “prospectus” within the meaning of the Securities Act or the Swedish Financial Instruments Trading Act. This presentation is only being provided to persons that are (i) “Qualified Institutional Buyers”, as defined in Rule 144A under the U.S. Securities Act, or (ii) outside the United States. B y attending this presentation or by reading the presentation slides, you warrant and acknowledge that you fall within one of the categories (i) and (ii) above. Any securities referred to herein have not been and will not be registered under the applicable securities laws of Canada, Australia or Japan and may not be offered or sold within Canada, Australia or Japan or to any national, resident or citizen of Canada, Australia or Japan. All of the Information herein has been prepared by the Company solely for use in this presentation. The Information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the Information or the opinions contained herein. The Information contained in this presentation should be considered in the context of the circumstances prevailing at that time and will not be updated to reflect material developments which may occur after the date of the presentation. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes. This presentation may contain certain forward-looking statements and forecasts which relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on the Company’s operations, financial position and earnings. The terms “anticipates”, “assumes”, “believes”, “can”, “could”, “e sti mates”, “expects”, “forecasts”, “intends”, “may”, “might”, “plans”, “should”, “projects”, “will”, “would” or, in each case, their negative, or other variations or comparable terminology are used to ident ify forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company’s control and could cause its actual results to differ materially from those it though t would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The Company does not undertake, and specifically decline, any obligation to update any such statements or to publicly announce the results of any revisions to any of such statements to reflect future events or developments. 2

Management Team Jonas s Ekb Ekblom, lom, CE CEO Jenni i Björ Björnulfson lfson, , CF CFO ▪ Over 25 years of experience from the life science ▪ More than 20 years of experience from the financial sector, with a focus in pharmacology and drug markets with a strong focus on the health care sector. development. ▪ Experience from Handelsbanken Markets, Alfred ▪ Experience from Bows Pharmaceuticals AG, Pharmacia, Berg/ABN AMRO, S&P, ABG Sundal Collier, GHP Biovitrum, Sequenom and Invitrogen ▪ Joined 2016 ▪ Ekblom has published over 60 peer-reviewed articles ▪ Joined 2010 Margit it Mahla lapuu, , CSO CSO Ulr lrika ika Wennberg, , COO COO ▪ Close to 20 years of experience in discovery and ▪ Over 20 years of business experience as an development of novel pharmaceuticals from the biotech entrepreneur, project manager, management consultant and pharma industry. and business leader. ▪ Experience from Arexis, AstraZeneca, Biovitrum ▪ Experience from Axelar, Jederström, Accenture ▪ Authored 50 articles in peer-reviewed scientific journals ▪ Joined 2009 and inventor on 7 pending patent applications.Professor in Molecular Medicine at Sahlgrenska Academy ▪ Joined 2007 3

Promore Pharma in Brief Two late stage, first-in-category products ▪ Human peptides for local administration with extraordinary safety ▪ Phase III – PXL01 Phase IIb – LL-37 ▪ Treating chronic wounds, mainly ▪ Preventing adhesions after tendon VLUs repair surgery No prescription drugs ▪ No prescription drugs ▪ 6 million patients in EU, NA & JP ▪ 1 million patients in EU, NA & JP ▪ ▪ Addressable global market 3 BUSD ▪ Addressable EU market 300 MUSD ▪ Indication broadening opportunities ▪ Indication broadening opportunities Vision To solve the global problems of scarring, adhesions and chronic wounds 4

Company Background 2003 - 2010 2010 - 2016 2017 - PXL Technology 2005; Gothenburg Two late stage clinical programs Merged under Pergamum in 2010 • • • ~ 20 programs LL-37 Technology • Cost-effective organization • ~ 30 employees 2003; Stockholm • No in-house laboratories Network of high-quality Part of the Karolinska • • CROs and CMOs Development group until 2015 DPK-060 Technology • Listed on Nasdaq First North Growth Market since 2017 2004; Lund Omniohealer BioCis Pharma Herantis Pharma shares 5

Peptides: A Unique Class of Therapeutics Ch Chemis mistry Biolog Biology Peptides present a combination of advantages compared to the most common drug classes Molecular weight (Da) 10 2 10 3 10 4 10 5 10 6 6

Local Delivery of Peptides: The Way to Go BIO BIOAVAIL AILABIL ILIT ITY Drug available at site of action in a medically relevant amount DURA DURATI TION Temporal exposure can readily be controlled through choice of formulation DOSING DOSI Flexible dosing by choice of injection volume SAFETY SAFE TY Rapid degradation of peptides in the bloodstream: very low systemic exposure 7

Trauma Has the Third Largest Spend 60 patients in the world, will contract a hard-to-heal wound, a dermal scar or Wounds, trauma and amputations a complication due to a post-surgical account for the third largest area of million adhesion every year healthcare spending in the world CNS Cardiovascular Trauma Oncology >600 600 400 300 USD billion 1) USD billion 1) USD billion 1) USD billion 1) 18% 15% 10% 27% of clinical studies 2) of clinical studies 2) of clinical studies 2) of clinical studies 2) 1) World Health Organization (WHO) 2018 8 2) Clinicaltrials.gov; an estimate of number of planned and ongoing clinical studies

PXL01